At the news
? NEUTRALIMPACT 4/10 8-K filed May 7, 2026 at 07:30 ET
Vera Therapeutics reported Q1 2026 results with a net loss of $1.69 per share, wider than the $0.81 loss in Q1 2025, driven by increased R&D and G&A spending ahead of a potential atacicept launch. The company maintains a strong cash position of $596.8M and is on track for a mid-2026 U.S. commercial launch pending FDA approval by July 7, 2026.
- Net loss per diluted share of $1.69 for Q1 2026 vs $0.81 in Q1 2025
- Cash, cash equivalents, and marketable securities of $596.8M as of March 31, 2026
- FDA PDUFA target action date for atacicept BLA is July 7, 2026
- Company expects U.S. commercial launch of atacicept in mid-2026, pending approval
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access